CYTH
Price:
$0.68
Market Cap:
$19.51M
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2000-05-03
Stock Exchange
NASDAQ
Ticker
CYTH
According to Cyclo Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.83. This represents a change of -49.93% compared to the average of -1.66 of the last 4 quarters.
The mean historical PE Ratio of Cyclo Therapeutics, Inc. over the last ten years is -10.44. The current -0.83 PE Ratio has changed 694.97% with respect to the historical average. Over the past ten years (40 quarters), CYTH's PE Ratio was at its highest in in the March 2022 quarter at 0.00. The PE Ratio was at its lowest in in the September 2014 quarter at -45.08.
Average
-10.44
Median
-5.62
Minimum
-54.58
Maximum
-0.78
Discovering the peaks and valleys of Cyclo Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 133.69%
Maximum Annual PE Ratio = -0.78
Minimum Annual Increase = -434.34%
Minimum Annual PE Ratio = -54.58
Year | PE Ratio | Change |
---|---|---|
2023 | -1.29 | 65.06% |
2022 | -0.78 | -52.78% |
2021 | -1.66 | 113.05% |
2020 | -0.78 | -83.74% |
2019 | -4.79 | -68.82% |
2018 | -15.37 | 133.69% |
2017 | -6.58 | 1.99% |
2016 | -6.45 | -46.77% |
2015 | -12.12 | -77.80% |
2014 | -54.58 | -434.34% |
The current PE Ratio of Cyclo Therapeutics, Inc. (CYTH) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.25
5-year avg
-1.86
10-year avg
-10.44
Cyclo Therapeutics, Inc.’s PE Ratio is less than Athenex, Inc. (-0.03), less than MedMen Enterprises Inc. (-0.00), less than Lifecore Biomedical, Inc. (12.14), less than Lucy Scientific Discovery Inc. (-0.72), greater than Guardion Health Sciences, Inc. (-2.89), less than Agile Therapeutics, Inc. (-0.65), greater than Alpha Teknova, Inc. (-5.47), less than Petros Pharmaceuticals, Inc. (-0.19), less than Phibro Animal Health Corporation (324.20), greater than SOHM, Inc. (-5.35), less than Silver Spike Investment Corp. (14.29), less than Eagle Pharmaceuticals, Inc. (5.10), greater than Intra-Cellular Therapies, Inc. (-90.48), less than Ironwood Pharmaceuticals, Inc. (77.85), greater than Amneal Pharmaceuticals, Inc. (-14.85), greater than Aquestive Therapeutics, Inc. (-14.78), less than Assertio Holdings, Inc. (-0.35), greater than AcelRx Pharmaceuticals, Inc. (-1.83),
Company | PE Ratio | Market cap |
---|---|---|
-0.03 | $2.33M | |
-0.00 | $138.32K | |
12.14 | $147.38M | |
-0.72 | $906.91K | |
-2.89 | $17.02M | |
-0.65 | $10.43M | |
-5.47 | $244.66M | |
-0.19 | $3.27M | |
324.20 | $788.20M | |
-5.35 | $2.05M | |
14.29 | $71.22M | |
5.10 | $55.19M | |
-90.48 | $7.77B | |
77.85 | $720.42M | |
-14.85 | $2.60B | |
-14.78 | $380.63M | |
-0.35 | $120.12M | |
-1.83 | $14.58M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cyclo Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Cyclo Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Cyclo Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Cyclo Therapeutics, Inc. (CYTH)?
What is the highest PE Ratio for Cyclo Therapeutics, Inc. (CYTH)?
What is the 3-year average PE Ratio for Cyclo Therapeutics, Inc. (CYTH)?
What is the 5-year average PE Ratio for Cyclo Therapeutics, Inc. (CYTH)?
How does the current PE Ratio for Cyclo Therapeutics, Inc. (CYTH) compare to its historical average?